HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HEPANOVA
- Sponsors Novocure Limited
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
- 08 Aug 2018 Planned End Date changed from 1 Jul 2021 to 1 Dec 2020.
- 08 Aug 2018 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2020.